Bellevue Asset Management AG
Filed a 13F-NT notice for 2026-06-30: this manager's Section 13(f) holdings are reported by another manager, so it no longer files its own holdings. Figures shown are from its last 13F-HR.
13F Reported Value
ⓘ$656,313
Holdings
127
Latest Filing
2015-12-31
Filing Quarter
Q4 2015
Portfolio Overview
Bellevue Asset Management AG disclosed 127 positions worth $656,313 in its Form 13F-HR for Q4 2015, followed by $BIIB and $GILD. During the quarter the fund opened 9 new positions and exited 15 — including a new stake in $IONS. The portfolio is most concentrated in Healthcare (62.6% of disclosed assets). All figures are sourced directly from Bellevue Asset Management AG’s Form 13F-HR filing with the SEC under CIK 1642343.
AI Fund Analysis
StableSector Allocation
13fpro.ai/research/fund/bellevue-asset-management-ag-1642343
AUM History
13fpro.ai/research/fund/bellevue-asset-management-ag-1642343
Top Equity Holdings by Value
13fpro.ai/research/fund/bellevue-asset-management-ag-1642343
Quarterly Activity — Q4 2015
Click any card to unlockTop Holdings
Celgene Corporation - COM
—Quality
$26.0K217,410 sh- 64.5#524
Quality
$25.7K84,030 sh - 57.3#1,079
Quality
$24.3K240,120 sh - 79.0
Quality
$20.0K123,000 sh - 70.7
Quality
$19.8K36,400 sh - 68.7
Quality
$19.7K256,500 sh - 60.2
Quality
$17.5K91,425 sh - 65.2
Quality
$17.1K381,500 sh Mylan Inc. - COM
—Quality
$17.0K315,300 sh- 58.8
Quality
$16.2K105,075 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| Celgene Corporation - COM | — | $26.0K | 217,410 |
| 64.5#524 | $25.7K | 84,030 | |
| 57.3#1,079 | $24.3K | 240,120 | |
| 79.0 | $20.0K | 123,000 | |
| 70.7 | $19.8K | 36,400 | |
| 68.7 | $19.7K | 256,500 | |
| 60.2 | $17.5K | 91,425 | |
| 65.2 | $17.1K | 381,500 | |
| Mylan Inc. - COM | — | $17.0K | 315,300 |
| 58.8 | $16.2K | 105,075 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Bellevue Asset Management AG's 127 positions.
Showing top 10 of 127 holdings.
Sector Allocation
Healthcare
$410,864
Other
$189,760
Consumer Staples
$30,426
Technology
$20,386
Financials
$4,877
Full Holdings — Bellevue Asset Management AG (Q4 2015)
All 127 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | — | Celgene Corporation - COM | $26,037 | 4.0% | -5% | — |
| 2 | BIOGEN INC. | $25,743 | 3.9% | +17% | 64.5 | |
| 3 | GILEAD SCIENCES, INC. | $24,298 | 3.7% | -5% | 57.3 | |
| 4 | AMGEN INC | $19,967 | 3.0% | +3% | 79 | |
| 5 | REGENERON PHARMACEUTICALS, INC. | $19,760 | 3.0% | -6% | 70.7 | |
| 6 | Medtronic plc | $19,730 | 3.0% | -5% | 68.7 | |
| 7 | ILLUMINA, INC. | $17,549 | 2.7% | +4% | 60.2 | |
| 8 | ABBOTT LABORATORIES | $17,133 | 2.6% | -18% | 65.2 | |
| 9 | — | Mylan Inc. - COM | $17,048 | 2.6% | +40% | — |
| 10 | BECTON DICKINSON & CO | $16,191 | 2.5% | +14% | 58.8 | |
| 11 | CARDINAL HEALTH INC | $15,308 | 2.3% | +114% | 62.3 | |
| 12 | UNITEDHEALTH GROUP INC | $14,117 | 2.1% | +0% | 62.5 | |
| 13 | STRYKER CORP | $13,077 | 2.0% | +0% | 71.9 | |
| 14 | TEVA PHARMACEUTICAL INDUSTRIES LTD | $11,600 | 1.8% | +4% | — | |
| 15 | — | Express Scripts Holding Company - COM | $10,839 | 1.6% | -23% | — |
| 16 | — | Endo International PLC - SHS | $10,469 | 1.6% | +8% | — |
| 17 | — | Auris Medical Holding AG - COM | $10,414 | 1.6% | +0% | — |
| 18 | ZIMMER BIOMET HOLDINGS, INC. | $9,797 | 1.5% | +0% | 65.4 | |
| 19 | — | Alexion Pharmaceuticals, Inc. - COM | $9,423 | 1.4% | +0% | — |
| 20 | CVS HEALTH Corp | $9,405 | 1.4% | +75% | 59.2 | |
| 21 | LIGAND PHARMACEUTICALS INC | $8,851 | 1.4% | -15% | 75.8 | |
| 22 | INCYTE CORP | $8,568 | 1.3% | +3% | 77.3 | |
| 23 | IONIS PHARMACEUTICALS INC | $8,546 | 1.3% | NEW | 22.9 | |
| 24 | BOSTON SCIENTIFIC CORP | $8,482 | 1.3% | +15% | 77.3 | |
| 25 | MCKESSON CORP | $8,481 | 1.3% | +5% | 63.2 | |
| 26 | Jazz Pharmaceuticals plc | $8,434 | 1.3% | +7% | — | |
| 27 | VERTEX PHARMACEUTICALS INC / MA | $8,431 | 1.3% | -19% | 75.2 | |
| 28 | — | St. Jude Medical, Inc. - COM | $7,536 | 1.1% | +0% | — |
| 29 | Cigna Group | $7,024 | 1.1% | -17% | 66 | |
| 30 | CENTENE CORP | $6,952 | 1.1% | +428% | 58.1 | |
| 31 | BIOMARIN PHARMACEUTICAL INC | $6,809 | 1.0% | +0% | 58 | |
| 32 | — | Insys Therapeutics, Inc. - COM NEW | $6,642 | 1.0% | +10% | — |
| 33 | Cencora, Inc. | $6,637 | 1.0% | +7% | 60.9 | |
| 34 | PERRIGO Co plc | $6,367 | 1.0% | +10% | — | |
| 35 | — | Shire PLC - SPONSORED ADR | $6,318 | 1.0% | -0% | — |
| 36 | INTUITIVE SURGICAL INC | $6,308 | 1.0% | -15% | 79.7 | |
| 37 | Coherus Oncology, Inc. | $5,901 | 0.9% | +12% | 4.9 | |
| 38 | — | Aetna Inc. - COM | $5,730 | 0.9% | +0% | — |
| 39 | HALOZYME THERAPEUTICS, INC. | $5,511 | 0.8% | +29% | 77 | |
| 40 | Edwards Lifesciences Corp | $5,450 | 0.8% | +55% | 69.2 | |
| 41 | HUMANA INC | $5,355 | 0.8% | +0% | 58.7 | |
| 42 | — | Horizon Pharma plc - SHS | $5,309 | 0.8% | +11% | — |
| 43 | Alkermes plc. | $5,199 | 0.8% | +11% | — | |
| 44 | JOHNSON & JOHNSON | $5,136 | 0.8% | +0% | 68.8 | |
| 45 | — | C.R. Bard, Inc. - COM | $5,115 | 0.8% | +10% | — |
| 46 | — | Mallinckrodt public limited company - SHS | $5,075 | 0.8% | -15% | — |
| 47 | — | Intersect Ent, Inc. - COM | $5,063 | 0.8% | +13% | — |
| 48 | EAGLE BANCORP INC | $4,877 | 0.7% | NEW | 24.1 | |
| 49 | SUPERNUS PHARMACEUTICALS, INC. | $4,771 | 0.7% | +11% | 41.8 | |
| 50 | COMMUNITY HEALTH SYSTEMS INC | $4,628 | 0.7% | +7% | 49.3 | |
| 51 | — | Achillion Pharmaceuticals, Inc. - COM | $4,532 | 0.7% | +0% | — |
| 52 | — | Lannett Inc. - COM | $4,312 | 0.7% | NEW | — |
| 53 | BAXTER INTERNATIONAL INC | $4,197 | 0.6% | +120% | 49.8 | |
| 54 | Elevance Health, Inc. | $4,183 | 0.6% | +0% | 58.8 | |
| 55 | BRISTOL MYERS SQUIBB CO | $4,127 | 0.6% | +0% | 70.1 | |
| 56 | HCA Healthcare, Inc. | $4,058 | 0.6% | +50% | 68.6 | |
| 57 | NEUROCRINE BIOSCIENCES INC | $3,677 | 0.6% | +0% | 76.2 | |
| 58 | NEKTAR THERAPEUTICS | $3,640 | 0.6% | -10% | 9.6 | |
| 59 | — | Cerner Corporation - COM | $3,610 | 0.6% | +9% | — |
| 60 | PFIZER INC | $3,551 | 0.5% | +29% | 61.8 | |
| 61 | AGIOS PHARMACEUTICALS, INC. | $3,506 | 0.5% | +0% | 26.3 | |
| 62 | — | Novadaq Technologies Inc. - COM | $3,185 | 0.5% | +0% | — |
| 63 | Merck & Co., Inc. | $3,169 | 0.5% | +0% | 59.7 | |
| 64 | HOLOGIC INC | $3,134 | 0.5% | +0% | 58.3 | |
| 65 | MASIMO CORP | $3,113 | 0.5% | +0% | 55.9 | |
| 66 | — | ARIAD Pharmaceuticals, Inc. - COM | $3,094 | 0.5% | +0% | — |
| 67 | — | Seattle Genetics, Inc. - COM | $3,052 | 0.5% | +42% | — |
| 68 | — | Medivation, Inc. - COM | $3,045 | 0.5% | +20% | — |
| 69 | — | Varian Medical Systems, Inc. - COM | $2,990 | 0.5% | +0% | — |
| 70 | ELI LILLY & Co | $2,949 | 0.5% | +0% | 87.5 | |
| 71 | THERMO FISHER SCIENTIFIC INC. | $2,837 | 0.4% | +0% | 64.9 | |
| 72 | NOVAVAX INC | $2,727 | 0.4% | +0% | 17.7 | |
| 73 | MACROGENICS INC | $2,571 | 0.4% | +0% | 39.5 | |
| 74 | QIAGEN N.V. | $2,530 | 0.4% | +14% | — | |
| 75 | Celldex Therapeutics, Inc. | $2,509 | 0.4% | +0% | 8.4 | |
| 76 | COOPER COMPANIES, INC. | $2,483 | 0.4% | +0% | 65.5 | |
| 77 | — | Radius Health Inc. - COM NEW | $2,462 | 0.4% | NEW | — |
| 78 | GLOBUS MEDICAL INC | $2,440 | 0.4% | +0% | 79.3 | |
| 79 | TELEFLEX INC | $2,439 | 0.4% | +0% | 37.4 | |
| 80 | — | Nuvasive, Inc. - COM | $2,435 | 0.4% | +0% | — |
| 81 | HEALTHCARE SERVICES GROUP INC | $2,267 | 0.3% | +0% | 60.7 | |
| 82 | ALNYLAM PHARMACEUTICALS, INC. | $2,259 | 0.3% | -25% | 71.2 | |
| 83 | — | Zeltiq Aesthetics Inc. - COM | $2,140 | 0.3% | NEW | — |
| 84 | — | Prothena Corporation plc - SHS | $2,111 | 0.3% | +107% | — |
| 85 | — | Intercept Pharmaceuticals, Inc. - COM | $2,016 | 0.3% | +55% | — |
| 86 | — | Bluebird Bio, Inc. - COM | $1,862 | 0.3% | +41% | — |
| 87 | — | Clovis Oncology, Inc. - COM | $1,838 | 0.3% | -5% | — |
| 88 | — | Stericycle, Inc. - COM | $1,809 | 0.3% | -25% | — |
| 89 | PTC THERAPEUTICS, INC. | $1,782 | 0.3% | NEW | 35.1 | |
| 90 | INOVIO PHARMACEUTICALS, INC. | $1,781 | 0.3% | +0% | 8.3 | |
| 91 | — | Wright Medical Group Inc. - ORD SHS 0.03 PAR | $1,700 | 0.3% | NEW | — |
| 92 | — | Juno Therapeutics, Inc. - COM | $1,627 | 0.3% | +12% | — |
| 93 | ACADIA PHARMACEUTICALS INC | $1,604 | 0.2% | -24% | 67.4 | |
| 94 | — | WellCare Health Plans, Inc. - COM | $1,564 | 0.2% | +0% | — |
| 95 | UNITED THERAPEUTICS Corp | $1,456 | 0.2% | +0% | 70.9 | |
| 96 | DAVITA INC. | $1,394 | 0.2% | +0% | 60.1 | |
| 97 | — | Infinity Pharmaceuticals, Inc. - COM | $1,256 | 0.2% | +23% | — |
| 98 | LABCORP HOLDINGS INC. | $1,236 | 0.2% | +0% | 64.6 | |
| 99 | ANGIODYNAMICS INC | $1,214 | 0.2% | +0% | 28.5 | |
| 100 | Ultragenyx Pharmaceutical Inc. | $1,122 | 0.2% | NEW | 34 | |
| 101 | — | Alder Biopharmaceuticals Inc. - COM | $1,090 | 0.2% | -23% | — |
| 102 | EXELIXIS, INC. | $959 | 0.1% | +13% | 75.9 | |
| 103 | Esperion Therapeutics, Inc. | $890 | 0.1% | +0% | 46.2 | |
| 104 | AbbVie Inc. | $889 | 0.1% | -44% | 72.5 | |
| 105 | — | Kite Pharma, Inc. - COM | $863 | 0.1% | -88% | — |
| 106 | — | Ishares TR - NASDQ BIOTEC ETF | $846 | 0.1% | +0% | — |
| 107 | — | Affymetrix, Inc. - COM | $807 | 0.1% | +0% | — |
| 108 | RESMED INC | $805 | 0.1% | +0% | 74.1 | |
| 109 | INSULET CORP | $794 | 0.1% | -7% | 71 | |
| 110 | — | Impax Laboratories, Inc. - COM | $770 | 0.1% | +0% | — |
| 111 | — | Team Health Holdings Inc. - COM | $658 | 0.1% | +0% | — |
| 112 | MYRIAD GENETICS INC | $604 | 0.1% | -58% | 24.3 | |
| 113 | Arbutus Biopharma Corp | $556 | 0.1% | +0% | 7.3 | |
| 114 | — | Juniper Pharmaceuticals Inc. - COM | $515 | 0.1% | +0% | — |
| 115 | — | Cadiovascular Systems Inc. - COM | $454 | 0.1% | +0% | — |
| 116 | — | MannKind Corporation - COM | $435 | 0.1% | +0% | — |
| 117 | — | Immunomedics, Inc. - COM | $407 | 0.1% | +0% | — |
| 118 | — | Endocyte, Inc. - COM | $401 | 0.1% | -37% | — |
| 119 | TENET HEALTHCARE CORP | $303 | 0.1% | -92% | 66 | |
| 120 | — | XOMA Corporation - COM | $299 | 0.1% | +0% | — |
| 121 | — | Heartware International, Inc. - COM | $252 | 0.0% | -89% | — |
| 122 | — | Tetraphase Pharmaceuticals, Inc. - COM | $221 | 0.0% | +0% | — |
| 123 | GERON CORP | $218 | 0.0% | +0% | — | |
| 124 | Theravance Biopharma, Inc. | $187 | 0.0% | +0% | 69.1 | |
| 125 | — | Celladon Corporation - COM | $74 | 0.0% | +0% | — |
| 126 | — | Asterias Biotherapeutics, Inc. - COM SER A | $7 | 0.0% | +0% | — |
| 127 | — | Biotime Inc. - W EXP 10/01/2018 | $3 | 0.0% | NEW | — |
New Positions (9)
Exited Positions (15)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Bellevue Asset Management AG including:
Track Bellevue Asset Management AG's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Bellevue Asset Management AG and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Bellevue Asset Management AG
13F Pro is an AI hedge fund tracker and stock research platform. For Bellevue Asset Management AG (SEC CIK: 1642343), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Bellevue Asset Management AG's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.